Genentech reports five-year data from trial of Susvimo for wet AMD

New five-year data on Susvimo implant for nAMD

Around 95% of people receiving treatment every six months required no supplemental treatment before each refill. Image: Anthony Kwan.New five-year data on Susvimo – a refillable implant that delivers continuous ranibizumab to the eye – has shown the treatment’s ability to maintain vision and retinal drying over a long period of time for people with neovascular age-related macular degeneration (nAMD). Drug manufacturer Roche revealed the new, fiv…

Genentech announces 5-Year data of susvimo for wet AMD from Portal study

The Portal study is a long-term extension of the phase 3 Archway study

Five-year data announced from phase 3 Portal study

Genentech reveals five-year data showing Susvimo effectively maintains vision in wet AMD patients with fewer injections, offering a promising treatment alternative.

Genentech Unveils Five-Year Data for Susvimo: Long-Term Efficacy and Durability in Wet AMD Treatment

Genentech announced new 5-year data from the phase 3 Portal study, which the company says reaffirms the long-term efficacy, safety, and durability of Susvimo (ranibizumab injection) in treating wet age-related macular degeneration (AMD). The findings were presented this week at the American Society of Retina Specialists (ASRS) 2025 annual meeting in Long Beach, CA. The Portal study, an extension of the phase 3 Archway trial, followed 352 patient…

Genentech reports five-year data from trial of Susvimo for wet AMD

Roche’s Genentech has reported new five-year data from the Phase III Portal trial of Susvimo for treating wet AMD.The post Genentech reports five-year data from trial of Susvimo for wet AMD appeared first on Clinical Trials Arena.